Long-term incidence of female-specific cancer after bariatric surgery or usual care in the Swedish Obese Subjects Study

Åsa Anveden, Magdalena Taube, Markku Peltonen, Peter Jacobson, Johanna C Andersson-Assarsson, Kajsa Sjöholm, Per-Arne Svensson, Lena M S Carlsson, Åsa Anveden, Magdalena Taube, Markku Peltonen, Peter Jacobson, Johanna C Andersson-Assarsson, Kajsa Sjöholm, Per-Arne Svensson, Lena M S Carlsson

Abstract

Objective: To examine the long-term effects of bariatric surgery on female-specific cancer in women with obesity.

Methods: The prospective, matched Swedish Obese Subjects (SOS) study was designed to examine outcomes after bariatric surgery. This study includes 1420 women from the SOS cohort that underwent bariatric surgery and 1447 contemporaneously matched controls who received conventional obesity treatment. Age was 37-60years and BMI was ≥38kg/m2. Information on cancer events was obtained from the Swedish National Cancer Registry. Median follow-up time was 18.1years (interquartile range 14.8-20.9years, maximum 26years). This study is registered with ClinicalTrials.gov, NCT01479452.

Results: Bariatric surgery was associated with reduced risk of overall cancer (hazard ratio=0.71; 95% CI 0.59-0.85; p<0.001). About half of the observed cancers were female-specific, and the incidence of these were lower in the surgery group compared with the control group (hazard ratio=0.68; 95% CI 0.52-0·88; p=0.004). The surgical treatment benefit with respect to female-specific cancer was significantly associated with baseline serum insulin (interaction p value=0.022), with greater relative treatment benefit in patients with medium or high insulin levels. Separate analyses of different types of female-specific cancers showed that bariatric surgery was associated with reduced risk of endometrial cancer (hazard ratio=0.56: 95% CI 0.35-0.89; p=0.014).

Conclusions: In this long-term study, bariatric surgery was associated with reduced risk of female-specific cancer, especially in women with hyperinsulinemia at baseline.

Funding: This project was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under Award Number R01DK105948 (the content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health), the Swedish Research Council K2013-99X-22279-01, K2013-54X-11285-19, Sahlgrenska University Hospital ALF research grant and Swedish Diabetes Foundation.

Keywords: Bariatric surgery; Endometrial cancer; Female-specific cancer; Gynecological cancer; Obesity.

Conflict of interest statement

Declaration of interests

LMSC has obtained lecture fees from AstraZeneca, Johnson&Johnson, and MSD. KS holds stocks in Pfizer. No other conflict of interest relevant to this study was reported.

Copyright © 2017 Elsevier Inc. All rights reserved.

Figures

Figure 1. Body weight changes after bariatric…
Figure 1. Body weight changes after bariatric surgery or usual care in women of the Swedish Obese Subjects Study
Error bars represent 95% confidence intervals.
Figure 2. Cumulative incidence of cancer events…
Figure 2. Cumulative incidence of cancer events after bariatric surgery or usual care in women of the Swedish Obese Subjects study
(A) overall cancer events and (B) female-specific cancer events. The x-axes are truncated at 22 years but all observations after 22 years were included in the analyses.
Figure 2. Cumulative incidence of cancer events…
Figure 2. Cumulative incidence of cancer events after bariatric surgery or usual care in women of the Swedish Obese Subjects study
(A) overall cancer events and (B) female-specific cancer events. The x-axes are truncated at 22 years but all observations after 22 years were included in the analyses.
Figure 3. Risk factor–treatment interactions for analyses…
Figure 3. Risk factor–treatment interactions for analyses for incidence of female-specific cancer events in the SOS study
Sub-grouping is based on tertiles of baseline values. (A) Incidence of first time female-specific cancer events. (B) Risk factor-treatment interactions for female-specific cancer events in subgroups. (C) Number needed to treat (NNT) over 10 years to prevent one female-specific cancer event.
Figure 4. Bariatric surgery and incidence of…
Figure 4. Bariatric surgery and incidence of different types of female-specific cancer
Number of events and incidence rates per 1000 person-years (IR/1000 p-yrs) are displayed separately for the surgery and control groups. Hazard ratio (HR) and 95% CI are shown by bars with dots.

Source: PubMed

3
Abonnieren